Jyothy Labs Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 12, 2025, 3:17 am

Competitors of Jyothy Labs Ltd

All Competitor Stocks of Jyothy Labs Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:43 am

Below is a detailed analysis of the quarterly data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 667.00 Cr.. The value appears to be declining and may need further review. It has decreased from 704.00 Cr. (Dec 2024) to 667.00 Cr., marking a decrease of 37.00 Cr..
• For Expenses, as of Mar 2025, the value is 555.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 589.00 Cr. (Dec 2024) to 555.00 Cr., marking a decrease of 34.00 Cr..
• For Operating Profit, as of Mar 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Dec 2024) to 112.00 Cr., marking a decrease of 4.00 Cr..
• For OPM %, as of Mar 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Dec 2024) to 17.00%, marking an increase of 1.00%.
• For Other Income, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 11.00 Cr., marking a decrease of 3.00 Cr..
• For Interest, as of Mar 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Dec 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Mar 2025, the value is 15.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Dec 2024) to 15.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Mar 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 114.00 Cr. (Dec 2024) to 107.00 Cr., marking a decrease of 7.00 Cr..
• For Tax %, as of Mar 2025, the value is 29.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Dec 2024) to 29.00%, marking an increase of 6.00%.
• For Net Profit, as of Mar 2025, the value is 76.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Dec 2024) to 76.00 Cr., marking a decrease of 11.00 Cr..
• For EPS in Rs, as of Mar 2025, the value is 2.08. The value appears to be declining and may need further review. It has decreased from 2.38 (Dec 2024) to 2.08, marking a decrease of 0.30.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:11 am

Growth

Last Updated: September 5, 2025, 8:35 am

Balance Sheet

Last Updated: November 9, 2025, 2:20 pm

Below is a detailed analysis of the balance sheet data for Jyothy Labs Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 37.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 37.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,013.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,772.00 Cr. (Mar 2024) to 2,013.00 Cr., marking an increase of 241.00 Cr..
• For Borrowings, as of Mar 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 51.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 10.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 580.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 542.00 Cr. (Mar 2024) to 580.00 Cr., marking an increase of 38.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 2,691.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,141.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,125.00 Cr. (Mar 2024) to 1,141.00 Cr., marking an increase of 16.00 Cr..
• For CWIP, as of Mar 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 9.00 Cr..
• For Investments, as of Mar 2025, the value is 456.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Mar 2024) to 456.00 Cr., marking an increase of 264.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,071.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1,071.00 Cr..
• For Total Assets, as of Mar 2025, the value is 2,691.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,401.00 Cr. (Mar 2024) to 2,691.00 Cr., marking an increase of 290.00 Cr..

Notably, the Reserves (2,013.00 Cr.) exceed the Borrowings (61.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Jyothy Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
• For Cash EPS (Rs.), as of Mar 25, the value is 11.62. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 11.62, marking an increase of 0.20.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 55.81. It has increased from 49.30 (Mar 24) to 55.81, marking an increase of 6.51.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 77.53. It has increased from 75.08 (Mar 24) to 77.53, marking an increase of 2.45.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.12. This value is within the healthy range. It has increased from 14.53 (Mar 24) to 15.12, marking an increase of 0.59.
• For PBIT / Share (Rs.), as of Mar 25, the value is 13.59. This value is within the healthy range. It has increased from 13.17 (Mar 24) to 13.59, marking an increase of 0.42.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 13.04 (Mar 24) to 13.31, marking an increase of 0.27.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 10.06 (Mar 24) to 10.09, marking an increase of 0.03.
• For PBDIT Margin (%), as of Mar 25, the value is 19.50. This value is within the healthy range. It has increased from 19.35 (Mar 24) to 19.50, marking an increase of 0.15.
• For PBIT Margin (%), as of Mar 25, the value is 17.52. This value is within the healthy range. It has decreased from 17.54 (Mar 24) to 17.52, marking a decrease of 0.02.
• For PBT Margin (%), as of Mar 25, the value is 17.16. This value is within the healthy range. It has decreased from 17.36 (Mar 24) to 17.16, marking a decrease of 0.20.
• For Net Profit Margin (%), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 10. It has decreased from 13.39 (Mar 24) to 13.00, marking a decrease of 0.39.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 13.01. This value is within the healthy range. It has decreased from 13.40 (Mar 24) to 13.01, marking a decrease of 0.39.
• For Return on Networth / Equity (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has decreased from 20.43 (Mar 24) to 18.07, marking a decrease of 2.36.
• For Return on Capital Employeed (%), as of Mar 25, the value is 22.89. This value is within the healthy range. It has decreased from 25.18 (Mar 24) to 22.89, marking a decrease of 2.29.
• For Return On Assets (%), as of Mar 25, the value is 13.76. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.76, marking a decrease of 1.62.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.24 (Mar 24) to 1.12, marking a decrease of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.37 (Mar 24) to 2.76, marking an increase of 0.39.
• For Quick Ratio (X), as of Mar 25, the value is 2.12. This value exceeds the healthy maximum of 2. It has increased from 1.78 (Mar 24) to 2.12, marking an increase of 0.34.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.31. This value exceeds the healthy maximum of 8. It has increased from 4.25 (Mar 24) to 9.31, marking an increase of 5.06.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 34.69. This value is within the healthy range. It has increased from 29.81 (Mar 24) to 34.69, marking an increase of 4.88.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.12. This value is within the healthy range. It has increased from 26.26 (Mar 24) to 30.12, marking an increase of 3.86.
• For Earning Retention Ratio (%), as of Mar 25, the value is 65.31. This value is within the healthy range. It has decreased from 70.19 (Mar 24) to 65.31, marking a decrease of 4.88.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.88. This value is within the healthy range. It has decreased from 73.74 (Mar 24) to 69.88, marking a decrease of 3.86.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 93.62. This value is within the healthy range. It has decreased from 112.80 (Mar 24) to 93.62, marking a decrease of 19.18.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 64.18. This value is within the healthy range. It has decreased from 79.08 (Mar 24) to 64.18, marking a decrease of 14.90.
• For Enterprise Value (Cr.), as of Mar 25, the value is 11,925.68. It has decreased from 15,977.96 (Mar 24) to 11,925.68, marking a decrease of 4,052.28.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.19. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 4.19, marking a decrease of 1.61.
• For EV / EBITDA (X), as of Mar 25, the value is 21.48. This value exceeds the healthy maximum of 15. It has decreased from 29.95 (Mar 24) to 21.48, marking a decrease of 8.47.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
• For Retention Ratios (%), as of Mar 25, the value is 65.30. This value is within the healthy range. It has decreased from 70.18 (Mar 24) to 65.30, marking a decrease of 4.88.
• For Price / BV (X), as of Mar 25, the value is 5.89. This value exceeds the healthy maximum of 3. It has decreased from 8.93 (Mar 24) to 5.89, marking a decrease of 3.04.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.24. This value exceeds the healthy maximum of 3. It has decreased from 5.86 (Mar 24) to 4.24, marking a decrease of 1.62.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness